Glaukos ( (GKOS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Glaukos Corp.’s stock is on the rise after the company announced promising results from its iDose TR Phase 3 trials, which demonstrated long-term efficacy and safety in reducing intraocular pressure. This positive news prompted analysts, including Stifel Nicolaus and BTIG, to raise their price targets, citing potential market expansion with Glaukos’s upcoming iDose TREX program. The company is also strengthening its market position by expanding surgeon training and securing therapy coverage. Despite these advancements, there is a contrasting negative sentiment from increased insider selling, though analysts maintain a ‘Strong Buy’ consensus on the stock.
More about Glaukos
YTD Price Performance: 0.06%
Average Trading Volume: 589,095
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.16B
For further insights into GKOS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.